HRP20031078A2 - Mycoplasma bovis vaccine and methods of reducing pneumonia in animals - Google Patents
Mycoplasma bovis vaccine and methods of reducing pneumonia in animals Download PDFInfo
- Publication number
- HRP20031078A2 HRP20031078A2 HR20031078A HRP20031078A HRP20031078A2 HR P20031078 A2 HRP20031078 A2 HR P20031078A2 HR 20031078 A HR20031078 A HR 20031078A HR P20031078 A HRP20031078 A HR P20031078A HR P20031078 A2 HRP20031078 A2 HR P20031078A2
- Authority
- HR
- Croatia
- Prior art keywords
- bovis
- vaccine
- mycoplasma bovis
- mycoplasma
- approximately
- Prior art date
Links
- 241001138504 Mycoplasma bovis Species 0.000 title claims description 217
- 229960005486 vaccine Drugs 0.000 title claims description 78
- 238000000034 method Methods 0.000 title claims description 63
- 241001465754 Metazoa Species 0.000 title claims description 56
- 206010035664 Pneumonia Diseases 0.000 title description 7
- 244000309466 calf Species 0.000 claims description 66
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 239000002671 adjuvant Substances 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 230000003053 immunization Effects 0.000 claims description 5
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 238000002649 immunization Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 244000052613 viral pathogen Species 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 42
- 210000004072 lung Anatomy 0.000 description 35
- 102000004169 proteins and genes Human genes 0.000 description 29
- 102000004196 processed proteins & peptides Human genes 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 229920001184 polypeptide Polymers 0.000 description 23
- 230000002163 immunogen Effects 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 20
- 241000283690 Bos taurus Species 0.000 description 18
- 238000002255 vaccination Methods 0.000 description 17
- 230000003902 lesion Effects 0.000 description 16
- 239000012634 fragment Substances 0.000 description 14
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 239000000902 placebo Substances 0.000 description 11
- 230000036760 body temperature Effects 0.000 description 9
- 231100000516 lung damage Toxicity 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 208000021017 Weight Gain Diseases 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 235000019786 weight gain Nutrition 0.000 description 7
- 230000004584 weight gain Effects 0.000 description 7
- 241000606831 Histophilus somni Species 0.000 description 6
- 241000202957 Mycoplasma agalactiae Species 0.000 description 6
- 241001148550 Mycoplasma bovirhinis Species 0.000 description 6
- 241000202954 Mycoplasma californicum Species 0.000 description 6
- 241001148552 Mycoplasma canis Species 0.000 description 6
- 241000006377 Mycoplasma dispar Species 0.000 description 6
- 241000202936 Mycoplasma mycoides Species 0.000 description 6
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 6
- 241000606856 Pasteurella multocida Species 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 229940051027 pasteurella multocida Drugs 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 229940031626 subunit vaccine Drugs 0.000 description 6
- 235000021052 average daily weight gain Nutrition 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000711895 Bovine orthopneumovirus Species 0.000 description 4
- 108010041986 DNA Vaccines Proteins 0.000 description 4
- 229940021995 DNA vaccine Drugs 0.000 description 4
- 241000204003 Mycoplasmatales Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 229960001212 bacterial vaccine Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- FBUKMFOXMZRGRB-UHFFFAOYSA-N Coronaric acid Natural products CCCCCC=CCC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101710170970 Leukotoxin Proteins 0.000 description 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- NKVLDFAVEWLOCX-GUSKIFEASA-N [(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxy-6-methyloxan-2-yl] (4ar,5r,6as,6br,9s,10s,12ar)-10-[(2r,3r,4s, Chemical compound O([C@H]1[C@H](O)CO[C@H]([C@@H]1O)O[C@H]1[C@H](C)O[C@H]([C@@H]([C@@H]1O)O)O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1OC(=O)[C@]12CCC(C)(C)CC1C1=CCC3[C@@]([C@@]1(C[C@H]2O)C)(C)CCC1[C@]3(C)CC[C@@H]([C@@]1(C)C=O)O[C@@H]1O[C@@H]([C@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O)C(=O)NCCCCCCCCCCCC)[C@@H]1OC[C@](O)(CO)[C@H]1O NKVLDFAVEWLOCX-GUSKIFEASA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 150000001793 charged compounds Polymers 0.000 description 2
- 229940001442 combination vaccine Drugs 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000019258 ear infection Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- -1 hydrocarbon ammonium halides Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229940023146 nucleic acid vaccine Drugs 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- JDRAOGVAQOVDEB-KTKRTIGZSA-N (3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl) (z)-octadec-9-enoate Chemical compound OC1COC2C(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC21 JDRAOGVAQOVDEB-KTKRTIGZSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30263801P | 2001-07-02 | 2001-07-02 | |
| PCT/IB2002/002514 WO2003004052A1 (fr) | 2001-07-02 | 2002-06-27 | Vaccin bovin contre la mycoplasmose et methodes permettant de reduire la pneumonie chez des animaux |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20031078A2 true HRP20031078A2 (en) | 2005-08-31 |
Family
ID=23168600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20031078A HRP20031078A2 (en) | 2001-07-02 | 2003-12-23 | Mycoplasma bovis vaccine and methods of reducing pneumonia in animals |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20030147914A1 (fr) |
| EP (1) | EP1401488A1 (fr) |
| JP (1) | JP2004536106A (fr) |
| KR (1) | KR20040030783A (fr) |
| CN (1) | CN1522152A (fr) |
| AP (1) | AP2002002568A0 (fr) |
| AR (1) | AR036125A1 (fr) |
| BG (1) | BG108496A (fr) |
| BR (1) | BR0210798A (fr) |
| CA (1) | CA2452580A1 (fr) |
| CZ (1) | CZ20033465A3 (fr) |
| EA (1) | EA200301324A1 (fr) |
| GT (1) | GT200200139A (fr) |
| HN (1) | HN2002000162A (fr) |
| HR (1) | HRP20031078A2 (fr) |
| HU (1) | HUP0501188A2 (fr) |
| IL (1) | IL159516A0 (fr) |
| IS (1) | IS7078A (fr) |
| MA (1) | MA27048A1 (fr) |
| MX (1) | MXPA03011815A (fr) |
| NO (1) | NO20035767L (fr) |
| OA (1) | OA12640A (fr) |
| PA (1) | PA8549801A1 (fr) |
| PE (1) | PE20030239A1 (fr) |
| PL (1) | PL373891A1 (fr) |
| SK (1) | SK15802003A3 (fr) |
| TN (1) | TNSN03154A1 (fr) |
| UY (1) | UY27365A1 (fr) |
| WO (1) | WO2003004052A1 (fr) |
| YU (1) | YU102103A (fr) |
| ZA (1) | ZA200309747B (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7179473B2 (en) | 1998-06-05 | 2007-02-20 | Boehringer Ingelheim Vetmedica Gmbh | Attenuated pestiviruses |
| US7135561B2 (en) | 2001-09-06 | 2006-11-14 | Boehringer Ingelheim Vetmedica Gmbh | Infectious bovine viral diarrhea virus clone |
| US7279166B2 (en) * | 2001-12-12 | 2007-10-09 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
| SE0301436D0 (sv) * | 2003-05-16 | 2003-05-16 | Joakim Westberg | New proteins |
| US7572455B2 (en) * | 2004-05-19 | 2009-08-11 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine comprising an attenuated pestivirus |
| UY29915A1 (es) * | 2005-11-15 | 2007-06-29 | Boehringer Ingelheim Vetmed | Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina |
| WO2008030619A2 (fr) * | 2006-09-07 | 2008-03-13 | Boehringer Ingelheim Vetmedica, Inc. | Génotypage à base de pcr |
| EP2377550B1 (fr) | 2006-09-11 | 2015-03-04 | Zoetis P LLC | Bactérines thermotraitées et vaccins en émulsion preparés à partir de telles bactérines thermotraitées |
| UY31437A1 (es) * | 2007-10-29 | 2009-05-29 | Vacuna de mycoplasma bovis y métodos de uso de la misma | |
| UY31930A (es) * | 2008-06-25 | 2010-01-29 | Boheringer Ingelheim Pharma Kg | Pestivirus atenuados recombinantes, en particular a csfv, bvdv o bdv atenuado recombinante |
| EP2320943B1 (fr) * | 2008-07-03 | 2016-02-17 | Iowa State University Research Foundation, Inc. | Vaccins pour le bétail |
| EP2362780B1 (fr) * | 2008-10-31 | 2019-12-25 | Boehringer Ingelheim Animal Health USA Inc. | Utilisation de divers antigènes y compris des antigènes provenant de mycoplasma bovis dans une composition de vaccin multivalente |
| US8846054B2 (en) * | 2009-01-09 | 2014-09-30 | Boehringer Ingelheim Vetmedica, Inc. | Method of treating pregnant cows and/or heifers |
| UY32570A (es) * | 2009-04-24 | 2010-11-30 | Boehringer Ingelheim Vetmed | Vacuna viva modificada de mycoplasma bovis mejorada |
| TWI583403B (zh) | 2009-06-04 | 2017-05-21 | 國立感染症研究所 | 黴漿菌感染症用疫苗 |
| CN102220263B (zh) * | 2011-05-06 | 2012-10-03 | 华中农业大学 | 一种牛支原体致弱菌株及其应用 |
| CN104968365B (zh) | 2012-12-28 | 2018-04-03 | 勃林格殷格翰动物保健有限公司 | 支原体疫苗的制备方法 |
| CN104857509A (zh) * | 2015-06-02 | 2015-08-26 | 福清市默克兽医院 | 牛支原体肺炎组织灭活疫苗的制备方法、配方及使用方法 |
| WO2017030901A1 (fr) | 2015-08-14 | 2017-02-23 | Zoetis Services Llc | Compositions à base de mycoplasma bovis |
| CN105441368B (zh) * | 2016-01-19 | 2019-01-01 | 福清市默克兽医院 | 一株牛支原体及其应用 |
| CN106929452B (zh) * | 2017-04-11 | 2020-06-12 | 河南省农业科学院畜牧兽医研究所 | 一株牛支原体及其应用 |
| CN109022314B (zh) * | 2018-08-06 | 2021-08-13 | 北京华夏兴洋生物科技有限公司 | 一株牛支原体及其在疫苗研制中的应用 |
| CN110338138B (zh) * | 2019-06-19 | 2021-04-06 | 山东省农业科学院奶牛研究中心 | 一种牛支原体感染豚鼠的动物模型构建方法及其应用 |
| CN112301041B (zh) * | 2020-10-09 | 2022-05-24 | 华中农业大学 | 牛支原体p21蛋白及其应用 |
| CN113546162B (zh) * | 2021-05-31 | 2023-07-18 | 江苏省农业科学院 | 一种支原体疫苗及其制备方法 |
| CN113604492B (zh) * | 2021-09-10 | 2023-07-07 | 苏州世诺生物技术有限公司 | 融合基因、融合蛋白及制备方法和牛支原体亚单位疫苗 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565205A (en) * | 1990-08-16 | 1996-10-15 | Solvay Animal Health, Inc. | Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof |
| EP1229929A2 (fr) * | 1999-11-08 | 2002-08-14 | Biomune | VACCINS CONTRE i MYCOPLASMA BOVIS /i ET LEURS PROCEDES D'UTILISATION |
| DE29921392U1 (de) * | 1999-12-06 | 2000-03-16 | Felgentraeger & Co Oeko Chem U | Mykoplasma-bovis-Kombinations-Vakzine für Rinder |
| US6548069B2 (en) * | 2001-02-03 | 2003-04-15 | Hmv Associates, Inc. | Multivalent Mycoplasma bacterin |
-
2002
- 2002-06-20 US US10/177,857 patent/US20030147914A1/en not_active Abandoned
- 2002-06-27 SK SK1580-2003A patent/SK15802003A3/sk not_active Application Discontinuation
- 2002-06-27 CZ CZ20033465A patent/CZ20033465A3/cs unknown
- 2002-06-27 OA OA1200300346A patent/OA12640A/en unknown
- 2002-06-27 IL IL15951602A patent/IL159516A0/xx unknown
- 2002-06-27 BR BRPI0210798-8A patent/BR0210798A/pt not_active IP Right Cessation
- 2002-06-27 WO PCT/IB2002/002514 patent/WO2003004052A1/fr not_active Application Discontinuation
- 2002-06-27 HU HU0501188A patent/HUP0501188A2/hu unknown
- 2002-06-27 MX MXPA03011815A patent/MXPA03011815A/es unknown
- 2002-06-27 CA CA002452580A patent/CA2452580A1/fr not_active Abandoned
- 2002-06-27 YU YU102103A patent/YU102103A/sh unknown
- 2002-06-27 PL PL02373891A patent/PL373891A1/xx unknown
- 2002-06-27 JP JP2003510062A patent/JP2004536106A/ja active Pending
- 2002-06-27 TN TNPCT/IB2002/002514A patent/TNSN03154A1/fr unknown
- 2002-06-27 CN CNA028132882A patent/CN1522152A/zh active Pending
- 2002-06-27 EP EP02738544A patent/EP1401488A1/fr not_active Withdrawn
- 2002-06-27 KR KR10-2004-7000003A patent/KR20040030783A/ko not_active Application Discontinuation
- 2002-06-27 EA EA200301324A patent/EA200301324A1/ru unknown
- 2002-06-27 AP APAP/P/2002/002568A patent/AP2002002568A0/en unknown
- 2002-06-28 HN HN2002000162A patent/HN2002000162A/es unknown
- 2002-07-01 AR ARP020102480A patent/AR036125A1/es unknown
- 2002-07-01 PE PE2002000592A patent/PE20030239A1/es not_active Application Discontinuation
- 2002-07-01 UY UY27365A patent/UY27365A1/es not_active Application Discontinuation
- 2002-07-02 GT GT200200139A patent/GT200200139A/es unknown
- 2002-07-02 PA PA20028549801A patent/PA8549801A1/es unknown
-
2003
- 2003-12-15 IS IS7078A patent/IS7078A/is unknown
- 2003-12-17 ZA ZA200309747A patent/ZA200309747B/xx unknown
- 2003-12-22 BG BG108496A patent/BG108496A/xx unknown
- 2003-12-22 NO NO20035767A patent/NO20035767L/no not_active Application Discontinuation
- 2003-12-23 HR HR20031078A patent/HRP20031078A2/hr not_active Application Discontinuation
- 2003-12-31 MA MA27469A patent/MA27048A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20033465A3 (cs) | 2004-12-15 |
| PE20030239A1 (es) | 2003-03-21 |
| UY27365A1 (es) | 2003-04-30 |
| EA200301324A1 (ru) | 2004-12-30 |
| MA27048A1 (fr) | 2004-12-20 |
| BR0210798A (pt) | 2006-05-23 |
| US20030147914A1 (en) | 2003-08-07 |
| JP2004536106A (ja) | 2004-12-02 |
| CA2452580A1 (fr) | 2003-01-16 |
| HUP0501188A2 (en) | 2006-05-29 |
| BG108496A (en) | 2005-02-28 |
| AR036125A1 (es) | 2004-08-11 |
| IL159516A0 (en) | 2004-06-01 |
| EP1401488A1 (fr) | 2004-03-31 |
| TNSN03154A1 (fr) | 2005-12-23 |
| WO2003004052A1 (fr) | 2003-01-16 |
| OA12640A (en) | 2006-06-15 |
| KR20040030783A (ko) | 2004-04-09 |
| HN2002000162A (es) | 2002-09-17 |
| PL373891A1 (en) | 2005-09-19 |
| PA8549801A1 (es) | 2003-09-17 |
| GT200200139A (es) | 2003-02-13 |
| IS7078A (is) | 2003-12-15 |
| NO20035767L (no) | 2004-01-30 |
| MXPA03011815A (es) | 2004-04-02 |
| AP2002002568A0 (en) | 2002-06-30 |
| CN1522152A (zh) | 2004-08-18 |
| ZA200309747B (en) | 2005-05-27 |
| SK15802003A3 (sk) | 2005-01-03 |
| YU102103A (sh) | 2006-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20031078A2 (en) | Mycoplasma bovis vaccine and methods of reducing pneumonia in animals | |
| AU2002309109B2 (en) | One dose vaccination with mycoplasma hyopneumoniae | |
| US7056492B2 (en) | Mycoplasma hyopneumoniae vaccine and methods for reducing Mycoplasma bovis pneumonia in cattle | |
| AU2002309109A1 (en) | One dose vaccination with mycoplasma hyopneumoniae | |
| JP2005500845A (ja) | マイコプラズマ・ボビスチャレンジモデル並びにマイコプラズマ・ボビスの投与方法及び肺炎性肺病変の誘発方法 | |
| CA2445997A1 (fr) | Vaccin | |
| AU2002304305B2 (en) | Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle | |
| AU2002311568A1 (en) | Mycoplasma bovis vaccine and methods of reducing pneumonia in animals | |
| AU2002304305A1 (en) | Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20050520 Year of fee payment: 4 |
|
| A1OB | Publication of a patent application | ||
| OBST | Application withdrawn |